The activity, safety, and evolving role of brigatinib in patients with ALK -rearranged non-small cell lung cancers

Brigatinib (AP26113) is a dimethylphosphine oxide group-containing tyrosine kinase inhibitor (TKI) constructed around a bisanilinopyrimidine scaffold with potent activity against the anaplastic lymphoma kinase (ALK) and several other targets. Despite the activity of first- and second-generation ALK...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	OncoTargets and therapy 2017-01, Vol.10, p.1983-1992
Hauptverfasser:	Sabari, Joshua K, Santini, Fernando C, Schram, Alison M, Bergagnini, Isabella, Chen, Ruqin, Mrad, Chebli, Lai, W Victoria, Arbour, Kathryn C, Drilon, Alexander
Format:	Artikel
Sprache:	eng
Schlagworte:	Adenosine triphosphate Binding sites Brigatinib Cancer therapies Chlorine Development and progression Drug dosages Drug therapy Growth factors Health aspects Hydrogen bonds Insulin Kinases Lung cancer Lymphoma Mutation Non-small cell lung cancer Oncology Review Targeted cancer therapy
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!